Attached files
| file | filename |
|---|---|
| EX-23.2 - EXHIBIT 23.2 - IMMUNE PHARMACEUTICALS INC | tv511125_ex23-2.htm |
| EX-10.42 - EXHIBIT 10.42 - IMMUNE PHARMACEUTICALS INC | tv511125_ex10-42.htm |
| EX-5.1 - EXHIBIT 5.1 - IMMUNE PHARMACEUTICALS INC | tv511125_ex5-1.htm |
| S-1/A - S-1/A - IMMUNE PHARMACEUTICALS INC | tv511125_s1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Immune Pharmaceuticals, Inc.
New York, New York
We consent to the inclusion in Amendment No. 2 to this Registration Statement of Immune Pharmaceuticals Inc. on Form S-1 of our report dated April 2, 2018, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Immune Pharmaceuticals Inc. as of December 31, 2017 and for the year then ended, which report appears in the Prospectus, which is part of this Registration Statement.
We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum LLP
Marcum LLP
New Haven, CT
January 16, 2019